Since B7-H3-expressing NSCLCs prevents CD8+ T cell-mediated immune surveillance, developing a new therapeutic modalities combination of anti-PD-1/PD-L1 with anti-B7-H3 immunotherapy to activate the anti-tumor activity of CD8+ T cell [171]. This evidence concerns the gene PDCD1 and neoplasm.